Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, Table of Contents CC BY 4.0 · Rev Bras Ginecol Obstet 2021; 43(07): 579-584DOI: 10.1055/s-0041-1735185 Febrasgo Position Statement Contraceptive counseling during the pandemic: practical guidelines Number 7 - July 2021 Edson Santos Ferreira Filho 1 Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil , Rogério Bonassi Machado 2 Departamento de Tocoginecologia, Faculdade de Medicina de Jundiaí, Jundiaí, SP, Brazil › Author Affiliations Recommend Article Abstract Full Text References References 1 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20 (05) 533-4 2 World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2020 [cited 2020 Dec 10]. Available from: http://covid19.who.int/ 3 Surita FGC, Luz AG, Hsu LPR, Carvalho FHC, Brock MF, Nakamura MU. Outpatient care for pregnant and puerperal women during the COVID-19 pandemic. Rev Bras Ginecol Obstet 2020; 42 (09) 588-92 4 Bietsch K, Williamson J, Reeves M. Family planning during and after the West African ebola crisis. Stud Fam Plann 2020; 51 (01) 71-86 5 Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol 2012; 120 (06) 1291-7 6 Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares-Júnior JM. et al. Contraception and reproductive planning during the COVID-19 pandemic. Expert Rev Clin Pharmacol 2020; 13 (06) 615-22 7 Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet 2012; 380 (9837): 149-56 8 Tang K, Gaoshan J, Ahonsi B, Ali M, Bonet M, Broutet N. et al. Sexual and reproductive health (SRH): a key issue in the emergency response to the coronavirus disease (COVID- 19) outbreak. Reprod Health 2020; 17 (01) 59 9 Short M, Bitzer J, Rowlands S. Testing times. Eur J Contracept Reprod Health Care 2020; 25 (03) 167-8 10 Le HH, Connolly MP, Bahamondes L, Cecatti JG, Yu J, Hu HX. The burden of unintended pregnancies in Brazil: a social and public health system cost analysis. Int J Womens Health 2014; 6: 663-70 11 Viellas EF, Domingues RMSM, Dias MAB, Gama SGN, Theme Filha MM, Costa JV. et al. Assistência pré-natal no Brasil. Cad Saúde Pública 2014; 30 (Suppl. 01) S85-100 12 Bellizzi S, Mannava P, Nagai M, Sobel HL. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle-income countries. Contraception 2020; 101 (01) 26-33 13 Caruso S, Rapisarda AMC, Minona P. Sexual activity and contraceptive use during social distancing and self-isolation in the COVID-19 pandemic. Eur J Contracept Reprod Health Care 2020; 25 (06) 445-8 14 Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M. et al. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet 2020; 395 (10231): 1175-7 15 Mmeje OO, Coleman JS, Chang T. Unintended consequences of the COVID-19 pandemic on the sexual and reproductive health of youth. J Adolesc Health 2020; 67 (03) 326-7 16 American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril 2014; 101 (03) 633-4 17 World Health Organization (WHO). Medical eligibility criteria for contraceptive use. Geneva: WHO; 2015 18 Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB. et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016; 65 (03) 1-103 19 The American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for Obstetrician–Gynecologists, Gynecology [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.acog.org/clinical-information/physician-faqs/covid19-faqs-for-ob-gyns-gynecology 20 Madden T, Secura GM, Nease RF, Politi MC, Peipert JF. The role of contraceptive attributes in women's contraceptive decision making. Am J Obstet Gynecol 2015; 213 (01) 46.e1-6 21 World Health Organization. Contraception/Family planning and COVID-19 [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.who.int/news-room/q-a-detail/contraception-family-planning-and-covid-19 22 Nanda K, Lebetkin E, Steiner MJ, Yacobson I, Dorflinger LJ. Contraception in the Era of COVID-19. Glob Health Sci Pract 2020; 8 (02) 166-8 23 United Nations Population Fund. Sexual and reproductive health and rights: modern contraceptives and other medical supply needs, including for COVID-19 prevention, protection and response [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.unfpa.org/sites/default/files/resource-pdf/COVID-19_Preparedness_and_Response_-_UNFPA_Interim_Technical_Briefs_Contraceptices_and_Medical_Supplies_23_March.pdf 24 Sorpreso ICE, Soares Júnior JM, Baracat EC. [Sexually vulnerable women: could reversible long-lasting contraception be the solution?]. Rev Bras Ginecol Obstet 2015; 37 (09) 395-6 25 Faculty of Sexual and Reproductive Healthcare. FSRH guidance for contraceptive provision after changes to Covid-19 lockdown [Internet]. 2020 [cited 2020 May 30]. Available from: https://www.fsrh.org/documents/fsrh-guidance-contraceptive-provision-changes-covid-lockdown/ 26 Federação Brasileira das Associações de Ginecologia e Obstetrícia. Comissão Nacional de Anticoncepção. Anticoncepção durante a pandemia por COVID-19 [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.febrasgo.org.br/en/covid19/item/1002-anticoncepcao-durante-a-pandemia-por-covid-19 27 Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception 2005; 72 (05) 337-41 28 United Nations Development Programme, United Nations Population Fund, World Health Organization, World Bank. Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56 (06) 341-52 29 Ti AJ, Roe AH, Whitehouse KC, Smith RA, Gaffield ME, Curtis KM. Effectiveness and safety of extending intrauterine device duration: a systematic review. Am J Obstet Gynecol 2020; 223 (01) 24-35.e3 30 Bahamondes L, Fernandes A, Bahamondes MV, Juliato CT, Ali M, Monteiro I. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: a chart review of 776 women in Brazil. Contraception 2018; 97 (03) 205-9 31 McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017; 216 (06) 586.e1-6 32 Prescribing information for Mirena [Internet]. 2020 [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021225s040lbl.pdf 33 Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S. et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod 2016; 31 (11) 2491-8 34 Thaxton L, Lavelanet A. Systematic review of efficacy with extending contraceptive implant duration. Int J Gynaecol Obstet 2019; 144 (01) 2-8 35 Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril 2016; 106 (06) 1289-94 36 Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (23 Suppl 1): I9-16 37 Asociación Española para el Estudio de la Menopausia, Sociedad Española de Ginecología y Obstetricia, Sociedad Española de Trombosis y Hemostasia. Riesgo tromboembólico en la pandemia de COVID-19 y tratamiento hormonal en mujeres perimenopausicas y postmenopausicas [Internet]. 2020 [cited 2020 Dec 6]. p. 1-9. Available from: https://www.covid-19.seth.es/riesgo-tromboembolico-en-la-pandemia-de-covid-19-y-tratamiento-hormonal-en-mujeres-perimenopausicas-y-postmenopausicas/ 38 Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N. et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemos. Maturitas 2020; 137: 57-62 39 Collège National des Enseignants de Gynécologie Médicale, L'Unité d'Hémostase Clinique de Cochin. Prévention du risque thromboembolique veineux chez les femmes COVID + non hospitalisées utilisant un traitement hormonal (Contraception, Traitement hormonal de ménopause, Tamoxifène) [Internet]. 2020 [cited 2020 Dec 10]. Available from: http://www.cngof.fr/coronavirus-go-cngof/apercu?path=HEMOSTASE%2B-%2BRISQUE%2BDE%2BMTE%252FHemostase-PreventionMVTECOVIDHormones.pdf&i=36239 40 de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T. et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; (03) CD010813 41 Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: a systematic review. Contraception 2016; 94 (06) 678-700 42 Pires ALR, Batista JG, Aldrighi JM, Massaia IFDS, Delgado DM, Ferreira-Filho ES. et al. Risk of venous thromboembolism in users of contraception and menopausal hormone therapy during the COVID-19 pandemic. Rev Assoc Med Bras (1992) 2020; 66 (Suppl. 02) 22-6
